Drugs / ATI-1013
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07215923 | Oct 2025 → Jun 2026 overdue | thromboangiitis obliterans | Antidote Therapeutics, Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-09-05 | Antidote Therapeutics, Inc | Regulatory Antidote Therapeutics Receives Orphan Drug Designation for ATI-1013 for the Treatment of Buerger’s Disease antidotetx.com ↗
Antidote Therapeutics, Inc., a biopharmaceutical company developing novel nicotine-blocking therapies to treat diseases caused or worsened by nicotine, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for ATI-1013, a fully human, anti-nicotine monoclonal antibody for the treatment of Buerger’s Disease. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-02-07 | Antidote Therapeutics, Inc | Antidote Therapeutics Announces Collaboration with National Cancer Institute to Develop ATI-1013 antidotetx.com ↗ |
| 2018-09-05 | Antidote Therapeutics, Inc | Antidote Therapeutics Receives Orphan Drug Designation for ATI-1013 for the Treatment of Buerger’s Disease antidotetx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATI-1013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07215923 ↗ |
| Modality | Monoclonal antibody | “a Human Monoclonal Antibody to Nicotine” NCT07215923 ↗ |
| Route | Intravenous | “Each participant will receive one intravenous (IV) infusion of ATI-1013 or placebo (Day 1).” NCT07215923 ↗ |